ERAS
Price
$2.54
Change
+$0.09 (+3.67%)
Updated
Dec 20 closing price
87 days until earnings call
RYTM
Price
$56.03
Change
+$0.55 (+0.99%)
Updated
Dec 20, 04:59 PM (EDT)
71 days until earnings call
Ad is loading...

ERAS vs RYTM

Header iconERAS vs RYTM Comparison
Open Charts ERAS vs RYTMBanner chart's image
Erasca
Price$2.54
Change+$0.09 (+3.67%)
Volume$2.43M
CapitalizationN/A
Rhythm Pharmaceuticals
Price$56.03
Change+$0.55 (+0.99%)
Volume$22.16K
CapitalizationN/A
ERAS vs RYTM Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. RYTM commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and RYTM is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ERAS: $2.54 vs. RYTM: $56.12)
Brand notoriety: ERAS and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 159% vs. RYTM: 260%
Market capitalization -- ERAS: $716.71M vs. RYTM: $3.45B
ERAS [@Biotechnology] is valued at $716.71M. RYTM’s [@Biotechnology] market capitalization is $3.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, RYTM is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 2 TA indicator(s) are bullish while RYTM’s TA Score has 2 bullish TA indicator(s).

  • ERAS’s TA Score: 2 bullish, 6 bearish.
  • RYTM’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, both ERAS and RYTM are a bad buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а -0.78% price change this week, while RYTM (@Biotechnology) price change was +1.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 20, 2025.

RYTM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.45B) has a higher market cap than ERAS($717M). RYTM YTD gains are higher at: 22.080 vs. ERAS (19.249). ERAS has higher annual earnings (EBITDA): -151.33M vs. RYTM (-237.01M). ERAS has more cash in the bank: 319M vs. RYTM (298M). RYTM has less debt than ERAS: RYTM (4.03M) vs ERAS (52.9M). RYTM has higher revenues than ERAS: RYTM (113M) vs ERAS (0).
ERASRYTMERAS / RYTM
Capitalization717M3.45B21%
EBITDA-151.33M-237.01M64%
Gain YTD19.24922.08087%
P/E RatioN/AN/A-
Revenue0113M-
Total Cash319M298M107%
Total Debt52.9M4.03M1,313%
FUNDAMENTALS RATINGS
RYTM: Fundamental Ratings
RYTM
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
34
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASRYTM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 11 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IGIAX101.211.21
+1.21%
Integrity Growth & Income Fund A
ICIEX21.660.25
+1.17%
Delaware Ivy Core Equity Fund Class I
EILGX18.230.20
+1.11%
Eaton Vance Atlanta Capital Focused Gr I
RICEX57.730.58
+1.01%
American Funds Invmt Co of Amer R4
TWEBX16.710.08
+0.48%
Tweedy, Browne Value

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with RCKT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+1.15%
RCKT - RYTM
48%
Loosely correlated
+1.85%
PLRX - RYTM
43%
Loosely correlated
-0.68%
ERAS - RYTM
43%
Loosely correlated
+3.67%
IDYA - RYTM
42%
Loosely correlated
+3.31%
PGEN - RYTM
42%
Loosely correlated
+5.07%
More